What is base editing and how does it differ from CRISPR gene editing?

CRISPR-Cas9 gene editing works by: Cas9 protein guided by RNA to a specific DNA sequence; Cas9 makes a double-strand break (cuts both strands of the DNA helix); the cell's DNA repair mechanisms fix the break — either disrupting the gene (NHEJ pathway) or incorporating a template sequence (HDR pathway). Problem: NHEJ repair is imprecise and can introduce insertions/deletions (indels) that may cause unintended effects; HDR is inefficient. Base editing (developed by David Liu at Broad Institute, licensed to Beam): uses a modified Cas9 that doesn't cut DNA; instead, a 'base editor' (fused to the Cas9 targeting domain) chemically converts one DNA base to another — e.g., converting cytosine (C) to thymine (T), or adenine (A) to inosine (read as G); no double-strand break means no indels from NHEJ; more predictable, precise editing. Base editing is ideal for correcting disease-causing point mutations — single-letter DNA changes responsible for conditions like sickle cell disease (a single A→T mutation in the HBB gene), familial hypercholesterolemia, and thousands of other genetic disorders.

What is sickle cell disease and how might base editing treat it?

Sickle cell disease (SCD) is a genetic blood disorder caused by a single point mutation in the HBB gene — one adenine (A) is changed to thymine (T) in position 6 of the beta-globin gene, changing glutamic acid to valine in the hemoglobin protein. This mutant hemoglobin (HbS) polymerizes under low oxygen conditions, distorting red blood cells into rigid 'sickle' shapes that block blood vessels, causing: severe pain crises (vaso-occlusive crises); organ damage (spleen, kidneys, lungs); stroke; reduced life expectancy. SCD affects approximately 100,000 Americans (predominantly of African ancestry) and millions globally. CRISPR-based treatments (Casgevy — approved 2023): reactivate fetal hemoglobin (HbF) production in patients' stem cells; HbF compensates for defective adult hemoglobin; requires stem cell extraction, editing, and reinfusion. Beam's BEAM-101 base editing approach: edits the SCD mutation directly or reactivates HbF through base editing of regulatory elements; potentially more precise and predictable than CRISPR double-strand break approaches; still in Phase 1 clinical trials.

How long does it take for a gene therapy company like Beam to reach FDA approval?

Gene therapy development timelines are long and uncertain: Preclinical (2-5 years) — cell culture and animal model testing; proof of concept for editing efficiency and safety; IND filing with FDA allowing first-in-human studies. Phase 1 clinical trial (1-3 years) — small number of patients (3-30); primary focus on safety; early efficacy signals; dose finding. Phase 2 clinical trial (2-4 years) — larger patient population (50-200); efficacy and safety; dose optimization; biomarker development. Phase 3 clinical trial (2-5 years) — large pivotal trial (100-500+ patients); randomized controlled evidence for regulatory approval; concurrent FDA review process (BLA or NDA filing). FDA BLA review (6-12 months) — FDA review of the complete data package; advisory committee meetings; potential approval. Total timeline from early preclinical to approval: 10-15+ years. Cost: $1-3 billion+ per approved therapy. Beam's early programs entered Phase 1 trials in 2022-2024; realistic FDA approval for first programs would be 2028-2032+ assuming successful trial results. This long development runway means investors in clinical-stage gene editing companies like Beam are making a bet on 5-10 year future value, with significant binary risk at each clinical stage.

Data as of: September 20, 2026

brimindinvest.com / compare / staa-vs-alny-geneLIVE

STAA

STAAR Surgical Company · Healthcare - Medical Devices

$20.82

-15.57% this month

VERSUS

COMPARE

BEAM

Beam Therapeutics Inc. · Healthcare - Gene Editing Biotechnology

$24.95

-14.17% this month

Comparison scoreboard

STAA LEADS 3/5

AI Scorei

STAA ✓44.3

BEAM 31.4

1Y Returni

STAA -23.34%

BEAM ✓-0.60%

Fwd P/Ei

STAA ✓22.57

BEAM -5.06

Target Up.i

STAA +20.73%

BEAM ✓+117.40%

Op. Margini

STAA ✓10.89%

BEAM -25827.14%

Metrics last refreshed: 9/20/2026

Quick take

STAA vs BEAM Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

STAA (STAAR Surgical) and BEAM (Beam Therapeutics) are both companies correcting biological issues through technology but at very different development stages — STAAR is a commercial medical device company generating revenue from its EVO ICL ophthalmic procedure with monopoly positioning in phakic IOLs, while Beam is a clinical-stage gene editing biotech with no revenue but exciting base editing technology potentially applicable to hundreds of genetic diseases years from commercialization.

STAA vs BEAM is commercial implantable lens with monopoly phakic IOL positioning (STAAR's EVO ICL reversible surgical vision correction for high-myopia patients with China growth exposure and sole-source competitive position among phakic IOLs) versus preclinical/clinical base editing gene therapy platform (Beam Therapeutics' precision DNA base conversion technology with sickle cell and CAR-T programs representing the next generation of genetic medicine) — commercial medical device compounder versus high-risk/high-reward gene editing platform.

Live analysis · updated 9/20/2026

STAA holds the edge across 3 of 5 key metrics in this comparison. BEAM has delivered stronger 1-year price return (-0.60% vs -23.34%), though STAA has the better forward P/E setup (22.57x vs -5.06x for BEAM). STAA leads on both revenue growth (111.00%) and operating margin (10.89%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BEAM (+117.40%) than for STAA (+20.73%).

Normalized 1Y performance

STAA

BEAM

Recent returns

STAA

BEAM

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

STAA

Price target range

analyst mean$27.90
current price$20.82

+20.7% upside to analyst mean

BEAM

Price target range

analyst mean$52.15
current price$24.95

+117.4% upside to analyst mean

Who should consider this stock?

STAA may suit investors who:

Want exposure to surgical vision correction with STAAR's monopoly phakic IOL position — EVO ICL is the only widely available surgical vision correction for patients who can't have LASIK, providing durable competitive moat
Value China's high myopia prevalence and rising middle class investment in premium healthcare as a structural long-term growth driver for EVO ICL procedure volumes
Prefer a commercial-stage, revenue-generating medical device company versus Beam's pre-revenue, clinical-stage profile with multi-year regulatory uncertainty

BEAM may suit investors who:

Believe base editing represents a generational advance in precision medicine — the ability to correct specific DNA mutations without double-strand breaks could enable treatments for thousands of genetic diseases currently untreatable
Accept the clinical-stage risk and multi-year commercialization timeline as appropriate for potentially transformative gene editing technology in sickle cell disease, metabolic disorders, and cancer immunotherapy
Want exposure to the next generation of gene therapy beyond CRISPR with a company that has foundational IP in base editing and multiple clinical programs demonstrating the technology's versatility

Performance & AI score

Performance & AI score
Metric	STAA	BEAM
AI scorei	44.3	31.4
AI ranki	#829	#2209
Latest closei	$20.82	$24.95
1M returni	-15.57%	-14.17%
6M returni	+18.84%	+1.30%
1Y returni	-23.34%	-0.60%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
Period	STAA	BEAM
1Y ago	$7.67K (-23.3%) started 2025-09-18	$9.94K (-0.6%) started 2025-09-18
5Y ago	$1.49K (-85.1%) started 2021-09-20	$2.62K (-73.8%) started 2021-09-20
10Y ago	$21.6K (+116.0%) started 2016-09-19	$13.31K (+33.1%) started 2020-02-06

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Valuation & upside potential
Metric	STAA	BEAM
Market capi	$1.16B	$2.48B
Trailing P/Ei	288.88	N/A
Forward P/Ei	22.57	-5.06
Price/Salesi	N/A	N/A
EV/Revenuei	3.04	9.56
Analyst targeti	$27.90	$52.15
Target upsidei	+20.73%	+117.40%

Growth, profitability & risk

Growth, profitability & risk
Metric	STAA	BEAM
Revenue growthi	111.00%	-94.20%
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	+4.52%	-154.99%
Operating margini	10.89%	-25827.14%
Profit margini	1.13%	-55.45%
ROIC proxyi	1.09%	-8.18%
Return on equityi	1.09%	-8.18%
Dividend yieldi	N/A	N/A
Payout ratioi	0.00%	0.00%
Dividend growth streaki	N/A	N/A
Betai	1.23	2.23
Debt/equityi	9.84	23.17
Current ratioi	4.67	14.57
Quick ratioi	3.86	14.25

Correlation

Over the past year, STAA and BEAM have moved barely in the same direction (correlation of 0.08), based on daily returns.

1Y

0.08

-1.0+1.0

5Y

0.34

-1.0+1.0

10Y

0.33

-1.0+1.0

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

STAA max drawdowni42.50%

BEAM max drawdowni39.08%

STAA max wkly dropi16.53%

BEAM max wkly dropi20.74%

5Y risk snapshot

STAA max drawdowni89.76%

BEAM max drawdowni85.32%

STAA max wkly dropi30.26%

BEAM max wkly dropi31.25%

10Y risk snapshot

STAA max drawdowni90.72%

BEAM max drawdowni89.12%

STAA max wkly dropi30.26%

BEAM max wkly dropi41.11%

Performance metrics by period

Performance metrics by period
Period	Metric	STAA	BEAM
1Y	Growthi	-23.34%	-0.60%
	CAGRi	-23.36%	-0.60%
	Volatilityi	55.38%	73.36%
	Sharpe ratioi	-0.29	0.29
	Sortino ratioi	-0.42	0.46
	Max drawdowni	42.50%	39.08%
	Current drawdowni	37.55%	34.20%
	Avg drawdowni	17.80%	17.93%
	Ulcer Indexi	21.77%	20.57%
	Max daily dropi	9.34%	10.48%
	Max wkly dropi	16.53%	20.74%
5Y	Growthi	-85.13%	-73.82%
	CAGRi	-31.73%	-23.54%
	Volatilityi	61.68%	74.95%
	Sharpe ratioi	-0.39	-0.05
	Sortino ratioi	-0.59	-0.07
	Max drawdowni	89.76%	85.32%
	Current drawdowni	85.87%	74.81%
	Avg drawdowni	68.70%	64.19%
	Ulcer Indexi	70.98%	66.68%
	Max daily dropi	24.68%	19.32%
	Max wkly dropi	30.26%	31.25%
10Y	Growthi	+115.98%	+33.07%
	CAGRi	+8.01%	+4.41%
	Volatilityi	58.18%	79.80%
	Sharpe ratioi	0.34	0.39
	Sortino ratioi	0.53	0.60
	Max drawdowni	90.72%	89.12%
	Current drawdowni	87.20%	81.32%
	Avg drawdowni	44.01%	60.59%
	Ulcer Indexi	54.16%	66.06%
	Max daily dropi	24.68%	23.42%
	Max wkly dropi	30.26%	41.11%

AI Prediction Signali

Members only

Next 5 trading days

STAA

+2.8%BUY

BEAM

+1.1%HOLD

Next 30 trading days

STAA

+6.4%BUY

BEAM

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	STAA	BEAM
Company	STAAR Surgical Company	Beam Therapeutics Inc.
Sector	Healthcare	Healthcare
Industry	Medical Instruments & Supplies	Biotechnology
Core business	STAAR Surgical is a medical device company focused on implantable lenses — primarily EVO Visian ICL (Implantable Collamer Lens), a biocompatible lens surgically inserted in front of the natural lens to correct myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. Unlike LASIK, the ICL doesn't remove corneal tissue — it's a reversible additive procedure for patients who want reduced dependence on glasses or contacts. STAAR is the only manufacturer of phakic IOLs (implants placed with the natural lens still in place) at commercial scale.	Beam Therapeutics is a clinical-stage biotechnology company developing base editing therapies — a precision gene editing technology that converts one DNA 'letter' (base) to another without making double-strand breaks in DNA. Beam's lead programs include: BEAM-101 (base editing for sickle cell disease), BEAM-301 (glycogen storage disease type Ia), and ex vivo CAR-T cell engineering programs using base editing to improve cancer immunotherapy. Base editing is a refinement of CRISPR — it enables more precise, predictable genetic corrections without the unintended insertion/deletions (indels) that CRISPR's double-strand break mechanism can cause.
Investor focus	Investors track STAAR's EVO ICL procedure volumes (particularly in China — a key growth market — and the U.S.), average selling price trends, market penetration versus LASIK, and the growth of EVO ICL acceptance among ophthalmologists and patients globally.	Investors track Beam's clinical trial results for its lead programs (particularly sickle cell and cancer CAR-T), the IND submissions and trial progress for base editing therapies, cash runway (Beam is pre-revenue), competitive positioning versus CRISPR-based therapies (Casgevy), and foundational patent estate strength.

STAA strengths

EVO ICL is the only widely available phakic IOL competitor to LASIK — STAAR is essentially a monopoly in the commercial phakic IOL market; patients with high myopia, thin corneas, or other LASIK contraindications who want surgical vision correction have limited alternatives to EVO ICL
Strong China market growth from high myopia prevalence — China has among the world's highest myopia prevalence rates (70%+ of urban Chinese young adults are myopic); rapidly growing Chinese middle class spending on premium eye care drives EVO ICL adoption
EVO ICL's reversibility differentiates versus LASIK for hesitant patients — EVO can be removed (LASIK cannot be reversed); this appeals to patients who want vision correction but are apprehensive about permanent LASIK changes; the additive, reversible nature addresses a common hesitation

BEAM strengths

Base editing technology addresses CRISPR's precision limitations — standard CRISPR creates double-strand DNA breaks; repair mechanisms can introduce unintended mutations (indels); base editing converts specific bases without breaks, providing more predictable outcomes; this precision advantage is critical for clinical therapeutics
Broad platform applicable to hundreds of genetic disease targets — base editing can theoretically correct any single-letter DNA mutation (point mutation) causing disease; with thousands of human genetic diseases caused by point mutations, Beam's platform has potentially vast applicability
Ex vivo CAR-T base editing collaboration with industry leaders — Beam has partnerships with major pharma companies for applying base editing to CAR-T cell engineering, providing validation of the technology and potential non-dilutive funding

Risks to watch — STAA

China regulatory and economic risk — STAAR's significant China revenue exposure creates sensitivity to regulatory changes, economic slowdowns, and U.S.-China trade tensions affecting medical device imports
LASIK and PRK competitive pressure from price competition — LASIK remains the most widely performed refractive surgery globally; LASIK improvements (SMILE procedure) and price competition may limit EVO ICL's market expansion pace
Myopia correction market competition from orthokeratology and low-dose atropine — non-surgical myopia management (specialty contact lenses, atropine eye drops) for children may reduce the pool of high-myopia adults seeking ICL surgery over time

Risks to watch — BEAM

All clinical programs are early-stage with regulatory approval still years away — Beam is pre-revenue with Phase 1/2 clinical trials underway; FDA approval for any program is likely 4-7+ years away; the company needs substantial funding to reach approval
Competition from CRISPR (Casgevy, approved for sickle cell) and prime editing — Vertex/CRISPR Therapeutics received the first CRISPR gene editing drug approval for sickle cell in 2023; Beam must demonstrate that base editing offers sufficient advantages over approved CRISPR therapies to justify adoption
Cash burn and financing requirements — Beam burns $200M+ annually on R&D; multiple rounds of equity financing are required to fund clinical development; shareholder dilution is substantial

Frequently asked questions

LASIK (Laser-Assisted In Situ Keratomileusis) reshapes the cornea with a laser to change how it focuses light — it permanently removes corneal tissue; the procedure is irreversible; it requires sufficient corneal thickness (patients with thin corneas are poor candidates); it has an excellent safety record for appropriate candidates. EVO Visian ICL (Implantable Collamer Lens) inserts a tiny biocompatible lens made of collamer (collagen + polymer) between the iris and the natural lens: no corneal tissue is removed; the procedure is reversible (lens can be removed); suitable for patients with high myopia, thin corneas, or other LASIK contraindications; EVO ICL can correct more extreme myopia (-3 to -20 diopters) than LASIK can safely address. Clinical studies show EVO ICL produces better optical quality and night vision compared to LASIK for high myopia patients. EVO ICL is more expensive than LASIK ($4,000-5,000 per eye versus $2,000-3,000 for LASIK). The ICL market is growing as awareness of LASIK alternatives increases and as the Chinese middle class invests in premium vision correction.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons